Arena expects to abandon Ph IIb-stage insomnia drug

12 January 2009

The USA's Arena Pharmaceuticals says that its insomnia drug candidate APD125 missed the primary and secondary endpoints in a Phase IIb trial.

Treatment with APD125 was well tolerated, and there were no reports of  serious adverse events and no emerging safety findings compared to  placebo. Arena is finishing a complete analysis of the data, but does  not anticipate developing it further.

"While we are disappointed and anticipated a different result based on  objective polysomnographic results from our previous studies, our  priority remains the successful development of lorcaserin, our  proprietary investigative treatment for obesity. We expect to announce  lorcaserin results from BLOOM, our first pivotal Phase III clinical  trial, around the end of March and to file a New Drug Application for  lorcaserin by the end of 2009," said Jack Lief, Arena's chief  executive.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight